Unlike large-cap names, AAME has essentially no active, attributable analyst price targets. Major aggregators show the one-year price target as unavailable, and the only published rating trail traces to rating services rather than equity research desks with formal targets. Because there is no usable analyst consensus, the $1.50 figure is a fallback objective drawn from publicly discussed valuation reasoning rather than a Wall Street forecast.
The core argument is the gap between the stock's market value and its balance sheet. Reported book value per share is roughly $5.90, yet the shares trade near $1.20, or about 0.21 times book. Even a partial re-rating to a still deeply discounted 0.25 times book would imply a price near $1.50. The 50-day moving average near $1.64 and the 200-day moving average near $1.87 sit above that level, making $1.50 a conservative first recovery milestone rather than a return to prior highs. This is a valuation-driven scenario, not a guarantee, and it should not be read as a published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
With the stock near $1.20, reaching $1.50 requires a gain of roughly 25%, which qualifies as a substantial move for a thinly traded micro-cap. The shares have been volatile, trading between about $1.01 and $3.22 over the past year, and are down more than 50% for 2026.
The company generated trailing revenue near $210 million with net income around $5.6 million and EPS (earnings per share) of about $0.28, implying a P/E (price-to-earnings ratio) near 4.4. A path toward $1.50 would most plausibly run through restored investor confidence: completing overdue financial reports, resolving the Nasdaq listing process, and convincing the market that reported book value is reliable. Until those conditions improve, the discount to book may persist or widen.
The stock is in a longer-term downtrend, trading well below its 50-day (near $1.64) and 200-day (near $1.87) moving averages. The 52-week low near $1.01 is the key downside support level, with the recent trading range roughly $1.10–$1.40. Above $1.50, the moving averages and the $2.00 psychological level form successive resistance zones, while the 52-week high near $3.22 marks the upper bound of recent memory. For a move toward $1.50 to hold, the shares would likely need to reclaim and hold the mid-$1.30s as new support.
In the absence of formal analyst targets, no standard 12-month research horizon applies to the $1.50 scenario. Investors should watch the Nasdaq Hearings Panel process and any filings completing the delayed quarterly reports, which could materially shift the outlook in either direction. Upcoming earnings and revenue results, dividend decisions, and any guidance on the insurance segments are also relevant. Because this is a balance-sheet story, changes in reported book value and reserve or actuarial adjustments in the life-and-health segment deserve particular attention.
Can Atlantic American (AAME) stock reach $1.50? The figure is attainable on paper given a book value near $5.90 and a price near $1.20, but it hinges on a re-rating that the market has so far been unwilling to grant. The central supports are the deep valuation discount, improved 2025 profitability, and a substantial cash position; the principal obstacles are the unresolved Nasdaq delisting process, a backlog of delayed filings, and thin liquidity. With no credible analyst consensus to lean on, investors should treat $1.50 as a valuation scenario requiring confirmation of restored reporting and compliance, not as a forecast or a recommendation.
In my own analysis, I often rely on Tickeron's AI Daily Buy/Sell Signals to track momentum shifts in thinly traded names like this. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. For a volatile micro-cap such as AAME, these signals provide an efficient way to spot changing trends and supplement independent research without needing to review every chart manually.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The Moving Average Convergence Divergence (MACD) for AAME turned positive on November 10, 2026. Looking at past instances where AAME's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on AAME as a result. In 79 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
Following a +10.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where AAME advanced for three days, in 160 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The 10-day RSI Indicator for AAME moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 similar instances where the indicator moved out of overbought territory. In 12 of the 14 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 53 of 56 cases where AAME's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
AAME moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AAME crossed bearishly below the 50-day moving average on November 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AAME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
AAME broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: AAME's P/B Ratio (0.207) is slightly lower than the industry average of (1.337). P/E Ratio (4.826) is within average values for comparable stocks, (19.773). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (0.463). Dividend Yield (0.072) settles around the average of (0.047) among similar stocks. AAME's P/S Ratio (0.134) is slightly lower than the industry average of (1.303).
The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. AAME’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AAME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 62, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of life, health, property and casualty insurance services
Industry LifeHealthInsurance